September 20, 2023

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub: Completion of US FDA Inspection at Unit IV of APL Healthcare Ltd. – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected the Unit IV, a Formulation manufacturing facility, of APL Healthcare Limited, a wholly owned subsidiary of the Company, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 13 to September 19, 2023.

At the end of the inspection, a 'Form 483' was issued with 1 observation which is procedural in nature. We will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observation at the earliest.

We will keep the stock exchanges further informed if there is any material information relating to the above in the future.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

Digitally signed by ADIREDDY BADDIGAM
Date: 2023.09.20 09:42:24 +05'30'

B. Adi Reddy
Company Secretary